Impact Report
We are particularly excited about two new clinical trials of small molecule drugs that target MYB—a key driver of ACC—for the first time ever.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features
- A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
- Deciphering the potential pathogeny of rare tracheal adenoid cystic carcinoma by single‑cell RNA‑sequencing
- Adenoid cystic carcinoma (ACC)
- DAY301 | Day One Biopharmaceuticals